Thailand announces plans for human trials after developing its second COVID-19 vaccine
4 min read
The vaccine which was developed by Chulalongkorn University showed promising results in prior trials with mice and monkeys. The University's Centre of Excellence in Vaccine Research and Development is utilizing new mRNA technology and its clinical testing on transgenic mice showed that the vaccine was able to prevent clinical symptoms and viremia after two shots. The university is looking to enroll 72 participants in the first phase of the human trials and subsequently increase the number to 300-600 participants in the second phase.
The university has also begun research on a second-generation vaccine that will help grant additional protection to its citizens against the UK and South African variants of the COVID-19 virus.

Why it matters

The impact of COVID-19 has been both far-reaching and devastating, causing numerous economic and social issues. The number of undernourished individuals is estimated to be at a staggering 690 million and could even rise to 132 million by the end of the year. Both business owners, as well as global corporations, have also had to bear the brunt of this pandemic and suffered tremendous losses, with most of them being unable to carry out their usual operations. Many others are also living on tethers, with an estimated 3.3 billion of the global workforce at risk of losing their jobs.…
Read full article